GLAXF GSK plc
Price Chart
Executive Summary
GSK announced FDA acceptance of its New Drug Application for bepirovirsen (chronic hepatitis B) with Priority Review and Breakthrough Therapy Designation, with a PDUFA date of October 26, 2026. The filing is supported by Phase III data showing statistically significant functional cure rates versus standard of care, addressing a large unmet need in a >250 million patient population. This is a positive regulatory milestone for a high-potential pipeline asset, though no financial terms or revenue estimates were disclosed.
Actionable Insight
The PDUFA date of October 26, 2026 provides a clear catalyst timeline. Traders should monitor for any FDA advisory committee meeting announcements and potential competitor developments (e.g., Arrowhead, Vir Biotechnology). Approval would unlock a significant new revenue stream for GSK's vaccines/specialty portfolio.
Key Facts
- FDA accepted NDA for bepirovirsen with Priority Review and Breakthrough Therapy Designation
- PDUFA goal date set for October 26, 2026
- Phase III B-Well 1 and B-Well 2 trials showed statistically significant and clinically meaningful functional cure rates
- Chronic hepatitis B affects >250 million people globally; current functional cure rates ~1%
- Bepirovirsen licensed from Ionis Pharmaceuticals; not yet approved anywhere
- Breakthrough Therapy Designation added to prior Fast Track Designation (Feb 2024)
Financial Impact
No financial figures disclosed; potential multi-billion-dollar peak sales if approved given large addressable patient population and high unmet need
Risk Factors
- Regulatory risk: FDA could issue Complete Response Letter or require additional trials
- Commercial risk: pricing/reimbursement uncertainty and competition from other HBV curative approaches
- Clinical risk: long-term durability data still pending; safety profile in broader populations unknown
Market Snapshot
Documents Analyzed
This report is based on 4 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001654954-26-003977 |
| Document: 0001654954-26-003977-index-headers.html | 0001654954-26-003977 |
| Document: 0001654954-26-003977-index.html | 0001654954-26-003977 |
| Document: 0001654954-26-003977.txt | 0001654954-26-003977 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
|
Jun 9, 2026
today
|
6-K
| — | awaiting T+5 | — | — |
|
Jun 9, 2026
today
|
6-K
| — | awaiting T+5 | — | — |
|
Jun 1, 2026
8d ago
|
6-K
| $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $24.66 (+1.69%) |
|
Jun 1, 2026
8d ago
|
6-K
| $24.25 $24.66 | ▲ +1.69% | ▲ +4.44% | $24.66 (+1.69%) |
|
May 28, 2026
12d ago
|
6-K
| $24.58 $24.66 | ▲ +0.33% | ▲ +0.01% | $24.66 (+0.33%) |
|
May 27, 2026
13d ago
|
6-K
| $25.57 $23.94 | ▼ −6.37% | ▼ −7.58% | $24.66 (−3.56%) |
|
May 26, 2026
14d ago
|
6-K
| $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $24.66 (−3.29%) |
|
May 26, 2026
14d ago
|
6-K
| $25.50 $24.25 | ▼ −4.90% | ▼ −5.99% | $24.66 (−3.29%) |
|
May 22, 2026
18d ago
|
6-K
| $26.00 $24.25 | ▼ −6.73% | ▼ −8.39% | $24.66 (−5.15%) |
|
May 20, 2026
20d ago
|
6-K
| $25.70 $25.57 | ▼ −0.51% | ▼ −1.74% | $24.66 (−4.05%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access